Delivered-To: tjphuhs@gmail.com Received: by 2002:adf:e74f:0:b0:439:fcfb:30e with SMTP id c15csp1130563wrn; Thu, 19 Mar 2026 11:13:53 -0700 (PDT) X-Received: by 2002:a05:622a:6852:20b0:50b:3601:52b4 with SMTP id d75a77b69052e-50b373f9142mr2582231cf.22.1773944033415; Thu, 19 Mar 2026 11:13:53 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1773944033; cv=none; d=google.com; s=arc-20240605; b=gv3j/LUgVb/+oBnbzDxMnwer/Dq+k32bjiZTA//RJlkS9lTQN3bWBsEwkNZqXSpiJu FyCKWDHMueKakL7tNigzbYoLHTxP3v62NynG/9D3zu83b/jacTVnUbhqOHcRHr+kbsOr rBHz2mLnTIlQYPQeHG6koY9sxA10ztcEbpMxmevQPx+EEn78GHUDqyRTLL7nRluFz9NZ YaWQkoPI92d3TcltciNDDmZE2PdUWIg9CsG0aAekW/S/l9BPsAJeRqDBCSjrCbKGbccb bXsPZKW5IA/9lGnUX+yCKbPCWrdPNS/G0P7Ku558SND/tDGXGjq44hMJr4LCC0a5/pc8 xKYQ== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=list-unsubscribe-post:list-unsubscribe:list-post:list-id :list-archive:list-url:list-owner:reply-to:in-reply-to:references :sender:feedback-id:date:message-id:to:from:subject:mime-version :dkim-signature:dkim-signature; bh=EvWWEL2l+YKNRa08I5+J3wCw7Um6FhzEaBq7K8KyAFo=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=PXBS2lkUFMbkvUBoT98zk99EZJgoqIkFGeudaMM+dLnPlzS5VOrbddPL1s9FoPNske mlggRTBwzZ24NCK6t3mMrVQY4S4epVvkpgzM7OCRkkIrzxfjXhioXZgDYB129rN8XnCj WW5oI3i6j6Ywhp9AmnD2yy8I3zd1pr2PyQlGmAFhQKrJr79QGq2fs7UZ0OwC4XJccA+f Mnw329cWapUztRRpWcoY/v564E9AbnjkklDOREAZno+pUu2dV+Onq910tjLWyfDRS2Iv 1LeB2HJGaZV57Ehvo3RBdFcQUvFvEThSuw2SQjAn44QLcKDeLtCQC9Pb4gMsblnU1Paw TmkA==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=WPI0jrG1; dkim=pass header.i=@mailgun.org header.s=mg header.b=ZsFvxd96; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.8 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com Return-Path: Received: from v58.v5375b7fa.use4.send.mailgun.net (v58.v5375b7fa.use4.send.mailgun.net. [159.112.244.8]) by mx.google.com with UTF8SMTPS id 6a1803df08f44-89c8537c241si4464566d6.577.2026.03.19.11.13.53 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Thu, 19 Mar 2026 11:13:53 -0700 (PDT) Received-SPF: pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.8 as permitted sender) client-ip=159.112.244.8; Authentication-Results: mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=WPI0jrG1; dkim=pass header.i=@mailgun.org header.s=mg header.b=ZsFvxd96; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.8 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mg-d0.substack.com; q=dns/txt; s=mailo; t=1773944032; x=1773951232; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=EvWWEL2l+YKNRa08I5+J3wCw7Um6FhzEaBq7K8KyAFo=; b=WPI0jrG1EUMaMavhN6Zqz+XPDzQshBLssQM9ONzTY1ILsJfYuXeqDO9pZZcXPX6iL1GpTKVmwhC1hyTYON7dR8rzQv2MBWC+KjYuy9aGHRggYoev4rhPVgmLYBr6ioUpNy3O5wjizVwsmyXEd1cKCSeYx6N6fGJAzebF+tou7l8= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1773944032; x=1773951232; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=EvWWEL2l+YKNRa08I5+J3wCw7Um6FhzEaBq7K8KyAFo=; b=ZsFvxd96h/V7McSQGPBbpgUG8gpeZBjLwkWK8itrxYpqeqpbCzyTWO5SetHyZuSlruim0kMxHdFt8QHaL/17G4sueB3sNiIR7l1eAGb3/JMyBCleL3i6J1nAXM6eq43K2UWfAhW61PZhPa/uzAJWnxKdRmMKj/uLJm5TdbuRW+U= X-Mailgun-Sid: WyJkZWU4NyIsInRqcGh1aHNAZ21haWwuY29tIiwiNjNhZjVkIl0= X-Feedback-Id: postmaster@mg-d0.substack.com:post:6148c7d8a45790427cda307f:mailgun Received: by e9ee55880790d515b4d723968c5cd4491322f6f4b35ddb5e802876b8c7271e36 with HTTP id 69bc3ce098e94a06ee0aa28e; Thu, 19 Mar 2026 18:13:52 GMT X-Mailgun-Sending-Ip: 159.112.244.8 Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="793deb9e022e34760f7f355cb49538fd600f3e7a38ba6d4d30c60e9e6aff" Subject: Do Semax and Selank Need to Be Cycled? From: Derek from Peptide Price To: tjphuhs@gmail.com X-Mailgun-Tag: post X-Mailgun-Track-Clicks: false Message-Id: <20260319181347.3.42d1c40801e6e6fb@mg-d0.substack.com> Date: Thu, 19 Mar 2026 18:13:47 +0000 Feedback-Id: post-191504977:cat-post:pub-3365367:substack Sender: Derek from Peptide Price References: In-Reply-To: Reply-To: Derek from Peptide Price List-Owner: List-Url: List-Archive: List-Id: List-Post: List-Unsubscribe: List-Unsubscribe-Post: List-Unsubscribe=One-Click X-Mailgun-Variables: {"category": "post", "email_generated_at": "1773944032139", "is_freemail": "true", "post_audience": "everyone", "post_id": "191504977", "post_type": "newsletter", "pub_community_enabled": "true", "publication_id": "3365367", "subdomain": "derekpruski", "user_id": "273622398"} --793deb9e022e34760f7f355cb49538fd600f3e7a38ba6d4d30c60e9e6aff Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable View this post on the web at https://derekpruski.substack.com/p/do-semax-an= d-selank-need-to-be-cycled I get this question constantly, so let=E2=80=99s address it directly. The short answer: it depends on the research protocol and administration fr= equency. Every research subject is going to respond a little differently. B= ut here=E2=80=99s the framework that makes sense for most protocols. What these compounds actually do Semax and Selank are neuropeptides =E2=80=94 they work on the brain=E2=80= =99s neurotrophic and anxiety-regulating systems rather than hormonal pathw= ays. Semax is primarily known for boosting BDNF (brain-derived neurotrophic= factor), enhancing focus, cognition, and mental clarity in research subjec= ts. Selank works on the GABAergic system and has anxiolytic effects =E2=80= =94 it reduces stress and anxiety markers in RS without sedation. Neither works like a stimulant where you see an immediate on/off effect. Th= e benefits build gradually and compound over time. That=E2=80=99s important= context for understanding how to structure research protocols. Why the effects build =E2=80=94 and why that matters for cycling With Semax, the building effect is tied to BDNF. Research =E2=80=94 primari= ly from animal models and some small human trials =E2=80=94 shows that BDNF= elevation doesn=E2=80=99t just spike and drop. It develops over repeated a= dministration and persists beyond the end of the protocol. BDNF promotes ac= tual structural changes in the brain over time, which is why researchers of= ten report that the cognitive effects feel more pronounced several weeks in= to a protocol than they did on day one. Selank=E2=80=99s effects on the GABAergic and serotonin systems follow a si= milar pattern. Research suggests the anxiolytic effects tend to stabilize a= nd strengthen over the course of a protocol rather than plateau or fade =E2= =80=94 though long-term human data here is still limited. Because these effects accumulate, you=E2=80=99re not working with something= that simply turns on and off. Neurological activity builds over time. And = just like anything that builds, it=E2=80=99s smarter to let the RS return t= o baseline periodically rather than keeping things constantly elevated. Run= ning a defined protocol with a deliberate break built in is the more though= tful approach =E2=80=94 and it gives you a cleaner read on how well the pro= tocol is actually working. The two approaches Option 1 =E2=80=94 Defined cycles with a break Run a 4=E2=80=938 week research protocol, then take 2=E2=80=934 weeks off. = This is the better approach for longer, higher-frequency protocols. Because= of the BDNF-driven building effect, many researchers note that cognitive a= nd mood benefits in RS persist well into the off period =E2=80=94 the washo= ut isn=E2=80=99t a cliff, it=E2=80=99s a gradual fade. You=E2=80=99re not l= osing everything the moment the protocol ends. Option 2 =E2=80=94 Intermittent use Some researchers run Semax or Selank on an as-needed basis =E2=80=94 a few = days on, a few days off, or situationally around high-demand periods. At lo= wer frequencies, the buildup effect is much less pronounced, and structured= cycling becomes largely unnecessary. This is a perfectly valid research ap= proach, especially when consistent daily effects aren=E2=80=99t the goal. The bottom line If you=E2=80=99re running a longer, consistent research protocol =E2=80=94 = build in 2=E2=80=934 weeks off afterward. It allows the RS to return to bas= eline and gives the next protocol a clean starting point. If the protocol i= s intermittent by design, there=E2=80=99s a lot more flexibility. Neither compound requires the rigid cycling structure you=E2=80=99d apply t= o something like a GHRH/GHRP stack. But keeping things constantly elevated = without a break isn=E2=80=99t the right call either. For research use only. Not for human consumption. Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXN= raS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSW= pveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVNVFV3TkRrM055d2lhV0YwSWpveE56Y3pPV= FEwTURNeUxDSmxlSEFpT2pFNE1EVTBPREF3TXpJc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lp= d2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5LkZOWjZObWtOTlVYdV9lYUNNNF9WQjBONU9= PTjM2dDRockQwZVY4V3h1Y0UiLCJwIjoxOTE1MDQ5NzcsInMiOjMzNjUzNjcsImYiOnRydWUsIn= UiOjI3MzYyMjM5OCwiaWF0IjoxNzczOTQ0MDMyLCJleHAiOjIwODk1MjAwMzIsImlzcyI6InB1Y= i0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.kKnUXojm37Z2nlpBm3I6dK9S4aoT-oL1d1ljx8H= OdeA? --793deb9e022e34760f7f355cb49538fd600f3e7a38ba6d4d30c60e9e6aff Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable Do Semax and Selank Need= to Be Cycled?3D""
I get this question constantly, so let’s address it directly.=
Forwarded this email? Subscribe here for more

Do Semax and Selank Need to Be= Cycled?

Derek
=
 
3D""
<= tbody>
3D""
3D""
=
= 3D""
<= /table>
=
READ IN APP3D""
 
=

I get this question constantly, so le= t’s address it directly.

The short answer: it depends= on the research protocol and administration frequency. Every research subj= ect is going to respond a little differently. But here’s the framewor= k that makes sense for most protocols.

3D""

What= these compounds actually do

Semax and Selank are = neuropeptides — they work on the brain’s neurotrophic and anxie= ty-regulating systems rather than hormonal pathways. Semax is primarily kno= wn for boosting BDNF (brain-derived neurotrophic factor), enhancing focus, = cognition, and mental clarity in research subjects. Selank works on the GAB= Aergic system and has anxiolytic effects — it reduces stress and anxi= ety markers in RS without sedation.

Neither works like a st= imulant where you see an immediate on/off effect. The benefits build gradua= lly and compound over time. That’s important context for understandin= g how to structure research protocols.

Why the effe= cts build — and why that matters for cycling

With Semax, the building effect is tied to BDNF. Research — primaril= y from animal models and some small human trials — shows that BDNF el= evation doesn’t just spike and drop. It develops over repeated admini= stration and persists beyond the end of the protocol. BDNF promotes actual = structural changes in the brain over time, which is why researchers often r= eport that the cognitive effects feel more pronounced several weeks into a = protocol than they did on day one.

Selank’s effects o= n the GABAergic and serotonin systems follow a similar pattern. Research su= ggests the anxiolytic effects tend to stabilize and strengthen over the cou= rse of a protocol rather than plateau or fade — though long-term huma= n data here is still limited.

Because these effects accumul= ate, you’re not working with something that simply turns on and off. = Neurological activity builds over time. And just like anything that builds,= it’s smarter to let the RS return to baseline periodically rather th= an keeping things constantly elevated. Running a defined protocol with a de= liberate break built in is the more thoughtful approach — and it give= s you a cleaner read on how well the protocol is actually working.

The two approaches

Option = 1 — Defined cycles with a break

Run a 4̵= 1;8 week research protocol, then take 2–4 weeks off. This is the bett= er approach for longer, higher-frequency protocols. Because of the BDNF-dri= ven building effect, many researchers note that cognitive and mood benefits= in RS persist well into the off period — the washout isn’t a c= liff, it’s a gradual fade. You’re not losing everything the mom= ent the protocol ends.

Option 2 — Intermitten= t use

Some researchers run Semax or Selank on an a= s-needed basis — a few days on, a few days off, or situationally arou= nd high-demand periods. At lower frequencies, the buildup effect is much le= ss pronounced, and structured cycling becomes largely unnecessary. This is = a perfectly valid research approach, especially when consistent daily effec= ts aren’t the goal.

The bottom line<= /p>

If you’re running a longer, consistent research proto= col — build in 2–4 weeks off afterward. It allows the RS to ret= urn to baseline and gives the next protocol a clean starting point. If the = protocol is intermittent by design, there’s a lot more flexibility.

Neither compound requires the rigid cycling structure you= 217;d apply to something like a GHRH/GHRP stack. But keeping things constan= tly elevated without a break isn’t the right call either.

For research use only. Not for human consumption.

You're currently a free sub= scriber to Peptide Price. = For the full experience, upgrade your subscription.

Upgrade to paid

=
 
 <= td>
3D""Share
 
3D"=Like<= /span>
<= tr><= /tr>
3D""Comment
3D""= Restack=
 

© 2026 Derek Pruski
548 Market Street PMB 72296, San Francisco, CA 9410= 4
Unsubscribe=

3D"Start

3D"" --793deb9e022e34760f7f355cb49538fd600f3e7a38ba6d4d30c60e9e6aff--